ANTI-PD-1 MONOCLONAL ANTIBODY AND OBTAINING METHOD THEREFOR

• US 20170240644A1
• Filed: 10/13/2015
• Published: 08/24/2017
• Est. Priority Date: 06/09/2015
• Status: Abandoned Application

• Current Assignee: Beijing Dongfang Biotech Co., Ltd., Beijing Jingyitaixiang Technology Development Co., Ltd.
• Original Assignee: Beijing Dongfang Biotech Co., Ltd., Beijing Jingyitaixiang Technology Development Co., Ltd.
• Inventors: ZHOU, Haiping, LI, Xiaomin, ZHOU, Junjie, PEI, Shuang, ZAN, Yanlu, BAI, Yi, BAI, Xianhong
• Application Number:
  US15/501,812
• Publication Number:
  US 20170240644A1
• Time in Patent Office: Days
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 16/005 constructed by phage libraries
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C12N 15/63 Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• CPC Class Codes: G01N 2333/70596 Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
• CPC Class Codes: G01N 33/577 involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens; G01N33/53 - G01N33/576 take precedence

Abstract

The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.

Claims

1. An anti-PD-1 monoclonal antibody comprises light chains and heavy chains, wherein the light chain contains three complementarity determining regions (CDRs) which are named as LCDR1, LCDR2 and LCDR3;

the LCDR1 comprises one of peptides whose amino acid sequences are shown as of SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23 or SEQ ID NO. 24;

the LCDR2 comprises one of the peptide whose amino acid sequences are shown as SEQ ID NO. 25, SEQ ID NO. 26, SEQ ID NO. 27, SEQ ID NO. 28, SEQ ID NO. 29 or SEQ ID NO. 30;

the LCDR3 comprises one of the peptides whose amino acid sequences shown as SEQ ID NO. 31, SEQ ID NO. 32, SEQ ID NO. 33, SEQ ID NO. 34, SEQ ID NO. 35, SEQ ID NO. 36 or SEQ ID NO. 37.

2. The anti-PD-1 monoclonal antibody according to claim 1, wherein the light chain contains a light chain variable region that is selected from one of the peptides having amino acid sequences shown as SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO. 8, SEQ ID NO.9, SEQ ID NO.10 or SEQ ID NO.11.

5. An antibody, a polypeptide or a protein thereof, wherein the antibody, the polypeptide or the protein contains one or more complementarity determining regions of claims 1 and 3.

6. A polynucleotide or combination of polynucleotides thereof, wherein the polynucleotide sequence or the combination encodes one or more complementarity determining regions of claims 1 and 3.

7. A recombinant DNA expression vector, wherein the recombinant DNA expression vector contains a polynucleotide sequence or combination encoding one or more complementarity determining regions of claims 1 and 3.

8. The recombinant DNA expression vector according to claim 7, wherein the recombinant DNA expression vector is transfected into a host cell, the host cell is selected from prokaryotic cells, yeasts, insects or mammalian cells.

9. The anti-PD-1 monoclonal antibody according to claims 1 and 3, wherein the anti-PD-1 monoclonal antibody is a human antibody;

the heavy chain having a constant region selected from IgG1, IgG2, IgG3 or IgG4;

the light chain having a constant region that is C_κ

or C_λ

.

10. A monoclonal antibody, a single-chain antibody, a single domain antibody, a bi-specific antibody or a drug-conjugated antibody, contains one or more complementarity determining regions of claims 1 and 3.

11. A monoclonal antibody, an artificial vector, a drug or a combination of drugs thereof, wherein the monoclonal antibody, the artificial vector, the drug or the combinations of drugs contains one or more complementarity determining regions of claims 1 and 3.

12. A detection reagent or a kit thereof, wherein the detection reagent or the kit contains one or more complementarity determining regions of claims 1 and 3.

3. An anti-PD-1 monoclonal antibody comprises light chains and heavy chains, wherein the heavy chain contains three complementarity determining regions which are named as HCDR1, HCDR2 and HCDR3;

the HCDR1 comprises one of peptides whose amino acid sequences were shown as SEQ ID NO. 38 or SEQ ID NO. 39;

the HCDR2 comprises one of peptides whose amino acid sequences were shown as SEQ ID NO. 40, SEQ ID NO. 41 or SEQ ID NO. 42;

the HCDR3 comprises one of peptides whose amino acid sequences were shown as SEQ ID NO. 43 or SEQ ID NO. 44.

4. The anti-PD-1 monoclonal antibody according to claim 3, wherein the heavy chain contains a heavy chain variable region that is selected from one of the peptides having amino acid sequences shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO. 4.